Compare WPRT & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WPRT | AYTU |
|---|---|---|
| Founded | 1995 | N/A |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.7M | 25.7M |
| IPO Year | 1995 | N/A |
| Metric | WPRT | AYTU |
|---|---|---|
| Price | $1.92 | $2.17 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $4.50 | ★ $9.33 |
| AVG Volume (30 Days) | 74.9K | ★ 81.9K |
| Earning Date | 03-30-2026 | 02-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $290,323,000.00 | $62,640,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $47.32 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 140.81 | 2.00 |
| 52 Week Low | $1.54 | $0.95 |
| 52 Week High | $4.77 | $3.07 |
| Indicator | WPRT | AYTU |
|---|---|---|
| Relative Strength Index (RSI) | 49.19 | 36.11 |
| Support Level | $1.85 | $2.13 |
| Resistance Level | $1.99 | $2.50 |
| Average True Range (ATR) | 0.10 | 0.14 |
| MACD | -0.01 | -0.05 |
| Stochastic Oscillator | 33.61 | 7.94 |
Westport Fuel Systems Inc is an organization engaged in the engineering, manufacturing, and supply of alternative fuel systems and components for transportation applications. It has three operating segments; the Original Equipment Manufacturers segment-design, manufacture, and sell alternative fuel systems, components and electronics, and related engineering services, to OEMs that serve light-duty, medium-duty, and heavy-duty customers, the Independent Aftermarket segment includes IAM products, conversion kits, and components allow for the conversion of vehicles after being sold to the end-user through a network of dealers and installers, and Corporate includes public company activities, corporate oversight, financing and capital allocation.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.